At a glance
- Originator Taisho Pharmaceutical
- Class Antihyperlipidaemics
- Mechanism of Action Cholesterol inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 19 Jan 2000 New profile
- 19 Jan 2000 Preclinical development for Hypercholesterolaemia in Japan (Unknown route)